l e t t e r s
MicroRNAs (miRNAs) are key regulators of gene expression in animals and plants. Studies in a variety of model organisms
show that miRNAs modulate developmental processes. To our knowledge, the only hereditary condition known to be caused by a miRNA is a form of adult-onset non-syndromic deafness 1 , and no miRNA mutation has yet been found to be responsible for any developmental defect in humans. Here we report the identification of germline hemizygous deletions of MIR17HG, encoding the miR-17~92 polycistronic miRNA cluster, in individuals with microcephaly, short stature and digital abnormalities. We demonstrate that haploinsufficiency of miR-17~92 is responsible for these developmental abnormalities by showing that mice harboring targeted deletion of the miR-17~92 cluster phenocopy several key features of the affected humans. These findings identify a regulatory function for miR-17~92 in growth and skeletal development and represent the first example of an miRNA gene responsible for a syndromic developmental defect in humans.
The MIR17HG locus encodes for miR-17~92, a polycistronic miRNA cluster from which six distinct miRNAs are produced ( Supplementary  Fig. 1 ). Genetic and functional studies have provided overwhelming evidence that this cluster is a bona fide human oncogene [2] [3] [4] [5] [6] [7] [8] [9] [10] . In addition, loss-of-function experiments in mice have shown that miR-17~92 is essential for mammalian development and that its complete inactivation leads to perinatal lethality 11 .
Feingold syndrome (MIM164280) is an autosomal dominant syndrome whose core features are microcephaly, relative short stature and digital anomalies, particularly brachymesophalangy of the second and fifth fingers and brachysyndactyly of the toes 12, 13 . Less penetrant defects include oesophageal, duodenal atresia (observed in 30-55% of cases), heart and kidney defects and variable learning disabilities. In approximately 70% of affected families, Feingold syndrome is caused by germline loss-of-function mutations of MYCN (MIM164840) at 2p24. 1 (refs. 14,15) , but the genetic lesion(s) responsible for the remaining cases have yet to be identified.
We employed high-resolution comparative genomic hybridization (CGH) arrays to perform a genome-wide analysis of ten index subjects with skeletal abnormalities consistent with a diagnosis of Feingold syndrome but who lacked any mutation at the MYCN locus (Supplementary Table 1 ). This led to the identification of germline hemizygous microdeletions at 13q31.3 in two subjects (AO39 II3 and AO70 II1; Figs. 1 and 2a) . The deletion in AO39 II3 spans 2.98 Mb and encompasses three genes: LOC144776, MIR17HG and GPC5 (Glypican-5). The deletion identified in AO70 II1 is more informative, as it spans 165 kb and encompasses only miR-17~92 and the first exon of GPC5 (Fig. 2a) . Quantitative PCR (qPCR) and direct sequencing of MIR17HG (including the promoter region) and of the GPC5 coding sequence failed to identify non-annotated sequence variations in the remaining eight index subjects (data not shown, and the primers used are listed in Supplementary Table 2) .
By genomic qPCR, we determined that the deletions detected in the two index subjects segregate with disease in the two families (Fig. 2b) , thus lending support to the hypothesis that these two microdeletions are the causative mutations in these individuals. Next, we queried the Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources (DECIPHER) database, which contains array CGH data from more than 6,000 individuals with a variety of disorders 16 , and identified an additional individual (subject id: 248412) harboring a 180-kb hemizygous 13q31.3 microdeletion encompassing the entire MIR17HG locus and the first exon of GPC5 (Figs. 1 and 2a) . This deletion was further confirmed by genomic qPCR (Fig. 2b) . Unfortunately, because of the lack of any genetic and clinical data from the parents of this individual, it is unclear whether the deletion was inherited or was de novo. Although not classified as having Feingold syndrome, this l e t t e r s subject has a combination of features compatible with a diagnosis of Feingold syndrome ( Fig. 1 and Supplementary Table 1) . The only exception to this was the presence of unusually hypoplastic thumbs, a trait we also observed in the affected father from family AO70 ( Fig. 1 and Supplementary Table 1 ) and one that is rarely as severe in individuals with Feingold syndrome with mutations in MYCN 15 . Analogous digital abnormalities were previously reported in some individuals with large 13q deletions 17, 18 ; however, because of the large size of the deletions, the gene(s) responsible for the developmental defects could not be identified.
To determine whether hemizygous loss of MIR17HG in humans results in a detectable reduction of miR-17~92 expression, we performed RT-qPCR on total RNA extracted from white blood cells obtained from three individuals carrying the 13q31.3 microdeletions. In these individuals, expression of all six miRNAs encoded by the miR-17~92 cluster was approximately 50% relative to control individuals (Fig. 2c) . This indicates that hemizygous loss of miR-17~92 results in a substantial reduction in the expression of its constituent miRNAs that is not compensated by upregulation of the remaining allele.
Together, these findings suggest that hemizygous deletion of MIR17HG and/or GPC5 is responsible for the skeletal abnormalities observed in these subjects, but they do not define the relative contribution of either gene. To address this issue, we first queried the Database of Genomic Variants 19 , which compiles structural variations detected in the genomes of healthy individuals (see URLs). We identified two Yoruba control individuals 20 heterozygous for a deletion encompassing exon 4 of GPC5 (Supplementary Fig. 2 ), which is predicted to produce a loss-of-function allele, as exon 3 and exon 5 are not in frame. Moreover, the 1000 Genomes browser (see URLs) reports a single nucleotide insertion in the coding sequence of GPC5 (rs34433071, c.1356_1357insC, p.Val454CysfsX7). Although the allelic frequency of this variant is currently unknown, the insertion is predicted to result in the loss of the 113 C-terminal amino acids of GPC5. In contrast, although a ~1.8-kb deletion ending 1.4 kb upstream of the first miRNA of the miR-17~92 cluster is reported in five normal individuals (Supplementary Fig. 2 ), we identified no structural variants or polymorphisms directly affecting the miRNAs encoded by the cluster in these databases. Collectively, these data indicate that hemizygous loss of GPC5 alone cannot account for the phenotypes observed in our subjects. To determine whether miR-17~92 haploinsufficiency can explain some of the defects observed in individuals harboring 13q31.1 microdeletions, we next examined the consequences of hemizygous deletion of this cluster in mice 11 .
Animals harboring targeted deletions of a single miR-17~92 allele (miR-17~92 ∆/+ ) are viable and fertile but are significantly smaller than wild-type controls 11 (Fig. 3a) , a feature also observed in both AO70   G   I   II   I1   I1  II1  II1   I1  II1  II3  II3   II3  II1  I1  II3 (Fig. 3b,c) , another feature observed in individuals with 13q31.3 microdeletions and in virtually all individuals with Feingold syndrome 15 . Other long bones in the hands of miR-17~92 ∆/+ mice were only marginally shorter than in wildtype mice (Fig. 3b and data not shown), and we did not observe syndactyly in any of the hemizygous animals. Analysis of the skulls of miR-17~92 ∆/+ mice revealed shortening of the anterior-posterior axis and an overall reduction in size, which are both consistent with microcephaly (Fig. 3d) . Notably, though Gpc5 and miR-17~92 are also closely linked in the mouse genome, targeted deletion of miR-17~92 does not negatively affect the expression of Gpc5 in the forelimbs of developing mouse embryos or in mouse embryo fibroblasts ( Supplementary Fig. 3 and data not shown), further showing that miR-17~92, but not Gpc5, is responsible for the key features observed in miR-17~92 ∆/+ mice and in individuals harboring 13q31.3 deletions.
Prompted by these findings, we examined the consequences of complete loss of miR-17~92 function on skeletal development. Because homozygous deletion of the cluster leads to perinatal lethality in mice 11 , we analyzed animals at embryonic day 18.5 (E18.5). Skeletal preparations of miR-17~92 ∆/∆ embryos revealed a severe and general delay of endochondral and membranous ossification (Fig. 4) . Notably, the main limb defects observed in individuals with Feingold syndrome were grossly exacerbated in these animals. More specifically, we observed the complete absence of the mesophalanx of the fifth digit, the presence of a small mesophalanx of the second digit and hypoplasia of the first digital ray (Fig. 4a and Supplementary  Fig. 4) . In addition, all embryos examined presented with fusion of the cervical vertebrae ( Fig. 4b and Supplementary Fig. 4 ) and microcephaly (Fig. 4c,d) . Additional skeletal defects consistently observed in these embryos included dysmorphic zeugopods and fusion of the proximal carpal bones (Fig. 4a and Supplementary Fig. 4) . In sum, the human genetic data and the analysis of miR-17~92 ∆/∆ and miR-17 ~92 ∆/+ mice show that miR-17~92 haploinsufficiency is responsible for developmental abnormalities in humans and highlight a previously unappreciated role for miR-17~92 in normal growth and skeletal development.
Based on the similarities between the skeletal defects observed in individuals with Feingold syndrome harboring MYCN mutations and in individuals with hemizygous deletion of MIR17HG, it is tempting to speculate that these two genes may be components of the same developmental pathways and that miR-17~92 may be an important target of MYCN in skeletal development. Fig. 5 and Supplementary Note) and can directly bind to the miR-17~92 promoter region in human and murine cells 21, 23, 24 ( Supplementary Fig. 6 ). Furthermore, ectopic expression of miR-17~92 cooperates with Myc in murine models of B-cell lymphoma and colorectal cancer 4, 25 . A possible cooperation between MYCN and miR-17~92 in modulating developmental processes is further supported by the remarkable similarity of the phenotypes observed in miR-17~92 ∆/∆ mice and in mice carrying hypomorphic or null Mycn alleles (Supplementary Table 3 ) [26] [27] [28] . One hypothesis emerging from these observations is that MYCN regulates various aspects of mammalian development through transactivation of miR-17~92. This hypothesis can be further refined by considering the phenotypic differences between mice carrying mutant alleles of Mycn and miR-17~92 and by comparing the consequences of MYCN and miR-17~92 loss in affected humans. For example, although individuals with Feingold syndrome with MYCN haploinsufficiency frequently present with gastrointestinal atresia (55% of cases) 15 , we did not observe this phenotype in any of the six individuals with mutant miR-17~92 described here nor did we observe it in miR-17~92 ∆/+ or miR-17~92 ∆/∆ mice (data not shown). Because abnormal gut development is reported in Mycn ∆/∆ mice 29, 30 (Supplementary Table 3 ), it seems plausible that MYCN controls gastrointestinal development independently of miR-17~92 or that miR-17~92 is functionally redundant. In contrast, microcephaly, short stature and brachymesophalangy are seen in humans and mice with mutated MYCN or miR-17~92, indicating functional cooperation between these two genes in skeletal development and growth.
Because none of the individuals with an MIR17HG deletion have gastrointestinal atresia, whether they should be classified as true cases of Feingold syndrome or as affected by a new form of brachydactyly with short stature and microcephaly remains an open question. Nevertheless, our results provide a strong rationale for testing all individuals with skeletal features of Feingold syndrome for mutations in both MYCN and MIR17HG.
At present, the detailed molecular mechanisms and the targets through which miR-17~92 modulates skeletal development remain unknown and will be the subject of future studies. Yet, it is worth noting that miR-17~92 has been shown to modulate the TGF-β and sonic hedgehog axes 6, 10, [31] [32] [33] , two of the most important signaling pathways controlling skeletal development and limb patterning.
Although our analysis of miR-17~92 ∆/+ mice clearly indicates that reduced dosage of this cluster can generate many of the skeletal phenotypes observed in individuals with Feingold syndrome with MYCN mutations and in individuals harboring 13q31.3 microdeletions, we cannot exclude the possibility that GPC5 haploinsufficiency also contributes to the pathogenesis of some of these phenotypes. In particular, it is possible that GPC5 haploinsufficiency plays a role in the severe thumb hypoplasia observed in some individuals carrying 13q31.3 microdeletions. Addressing this issue will require the identification and characterization of additional families carrying deletions of this region and the generation of miR-17~92 and Gpc5 compound-mutant animals.
In conclusion, this study provides the first evidence, to our knowledge, of a germline mutation of an miRNA gene leading to a developmental defect in humans. Together with the previous report of mutation of miR-96 in adult-onset hereditary deafness 1 , miR-17~92 represents the only other known example of an miRNA directly responsible for a hereditary disease in humans. Our results also expand the known biological activities of a major oncogenic miRNA cluster by showing its role in skeletal growth and patterning and suggest a possible functional interaction between MYCN and miR-17~92 in modulating embryonic development. 
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